[{"to": "295", "prefix": "ivity and compare them to a clinically recognized inducer, ", "from": "288", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1865122.txt", "exact": "rifampin", "suffix": ", and inhibitor, clarithromycin. Healthy volunteers were ran"}, {"to": "497", "prefix": " supplement for 14 days. Subjects also received ", "from": "490", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1865122.txt", "exact": "rifampin", "suffix": " "}, {"to": "761", "prefix": "control period. The effects of milk thistle, black cohosh, ", "from": "754", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1865122.txt", "exact": "rifampin", "suffix": ", and clarithromycin on midazolam pharmacokinetics were dete"}, {"to": "897", "prefix": "ing noncompartmental techniques. Unlike those observed for ", "from": "890", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1865122.txt", "exact": "rifampin", "suffix": " and clarithromycin, midazolam pharmacokinetics were unaffec"}, {"to": "6331", "prefix": "e the effects of milk thistle and black cohosh to those of ", "from": "6324", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1865122.txt", "exact": "rifampin", "suffix": ", an inducer of CYP3A4 expression,39 and clarithromycin, an "}, {"to": "7906", "prefix": "cation regimens\n\nThe effect of milk thistle, black cohosh, ", "from": "7899", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1865122.txt", "exact": "rifampin", "suffix": " and clarithromycin on midazolam pharmacokinetics was evalua"}, {"to": "8191", "prefix": " refers either to milk thistle, black cohosh, ", "from": "8184", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1865122.txt", "exact": "rifampin", "suffix": ", or clarithromycin."}, {"to": "8323", "prefix": "", "from": "8316", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1865122.txt", "exact": "rifampin", "suffix": " or clarithromycin"}, {"to": "8880", "prefix": " ", "from": "8873", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1865122.txt", "exact": "Rifampin", "suffix": " "}, {"to": "9326", "prefix": "; ", "from": "9319", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1865122.txt", "exact": "rifampin", "suffix": " "}, {"to": "17661", "prefix": "hour after MDZ dosing were used to estimate the effects of ", "from": "17654", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1865122.txt", "exact": "rifampin", "suffix": ", clarithromycin, milk thistle, and black cohosh on CYP3A ph"}, {"to": "20872", "prefix": "loration of the urine were common conditions reported with ", "from": "20865", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1865122.txt", "exact": "rifampin", "suffix": " use. Three subjects noted an increase in headaches while ta"}, {"to": "21486", "prefix": "iceable effect on the duration of MDZ-induced sleep. After ", "from": "21479", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1865122.txt", "exact": "rifampin", "suffix": ", however, most subjects either did not sleep or their sleep"}, {"to": "21696", "prefix": "4 hours.\n\nThe effects of clarithromycin, ", "from": "21689", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1865122.txt", "exact": "rifampin", "suffix": ", milk thistle, and black cohosh on serum MDZ concentration "}, {"to": "22464", "prefix": ", Cmax, and elimination half-life were noted following ", "from": "22457", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1865122.txt", "exact": "rifampin", "suffix": " administration "}, {"to": "22509", "prefix": ". ", "from": "22502", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1865122.txt", "exact": "Rifampin", "suffix": " increased MDZ apparent oral clearance by more than 20 fold "}, {"to": "22710", "prefix": " significant reduction in Tmax was also observed following ", "from": "22703", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1865122.txt", "exact": "rifampin", "suffix": " "}, {"to": "22755", "prefix": ". In contrast to ", "from": "22748", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1865122.txt", "exact": "rifampin", "suffix": " and clarithromycin, no significant changes in MDZ pharmacok"}, {"to": "23015", "prefix": "ncentration-time profiles before and after clarithromycin. ", "from": "23008", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1865122.txt", "exact": "rifampin", "suffix": ", milk thistle and black cohosh. Black squares "}, {"to": "23652", "prefix": "i.e., change in pre- versus post-", "from": "23645", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1865122.txt", "exact": "rifampin", "suffix": " CL"}, {"to": "24533", "prefix": "phenotypes was noted after each treatment phase. Mean post-", "from": "24526", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1865122.txt", "exact": "rifampin", "suffix": " 1-hour HMDZ"}, {"to": "25274", "prefix": " ", "from": "25267", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1865122.txt", "exact": "Rifampin", "suffix": ", "}, {"to": "26565", "prefix": "istration of clarithromycin, a known CYP3A4 inhibitor, and ", "from": "26558", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1865122.txt", "exact": "rifampin", "suffix": ", a recognized inducer of CYP3A4 expression. In addition, ou"}, {"to": "31534", "prefix": "lier,12 indicate that, when compared to clarithromycin and ", "from": "31527", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1865122.txt", "exact": "rifampin", "suffix": ", recommended doses of black cohosh triterpene glycosides do"}, {"to": "35719", "prefix": "pproaches.\n\nIn conclusion, when compared to the effects of ", "from": "35712", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1865122.txt", "exact": "rifampin", "suffix": " and clarithromycin, the specific brand of milk thistle and "}, {"to": "8889", "prefix": "", "from": "8883", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/MESH/D012293", "setId": "PMC1865122.txt", "exact": "Rifadin", "suffix": ""}, {"to": "326", "prefix": " a clinically recognized inducer, rifampin, and inhibitor, ", "from": "313", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC1865122.txt", "exact": "clarithromycin", "suffix": ". Healthy volunteers were randomly assigned to receive a sta"}, {"to": "525", "prefix": " and ", "from": "512", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC1865122.txt", "exact": "clarithromycin", "suffix": " "}, {"to": "781", "prefix": ". The effects of milk thistle, black cohosh, rifampin, and ", "from": "768", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC1865122.txt", "exact": "clarithromycin", "suffix": " on midazolam pharmacokinetics were determined using noncomp"}, {"to": "916", "prefix": "tmental techniques. Unlike those observed for rifampin and ", "from": "903", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC1865122.txt", "exact": "clarithromycin", "suffix": ", midazolam pharmacokinetics were unaffected by milk thistle"}, {"to": "6386", "prefix": " those of rifampin, an inducer of CYP3A4 expression,39 and ", "from": "6373", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC1865122.txt", "exact": "clarithromycin", "suffix": ", an inhibitor of CYP3A4 activity,40 as a means of gauging t"}, {"to": "7925", "prefix": "ns\n\nThe effect of milk thistle, black cohosh, rifampin and ", "from": "7912", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC1865122.txt", "exact": "clarithromycin", "suffix": " on midazolam pharmacokinetics was evaluated individually on"}, {"to": "8210", "prefix": " refers either to milk thistle, black cohosh, rifampin, or ", "from": "8197", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC1865122.txt", "exact": "clarithromycin", "suffix": "."}, {"to": "8341", "prefix": "rifampin or ", "from": "8328", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC1865122.txt", "exact": "clarithromycin", "suffix": ""}, {"to": "8953", "prefix": " and ", "from": "8940", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC1865122.txt", "exact": "clarithromycin", "suffix": " "}, {"to": "8961", "prefix": "", "from": "8956", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC1865122.txt", "exact": "Biaxin", "suffix": ""}, {"to": "9368", "prefix": "; and ", "from": "9355", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC1865122.txt", "exact": "clarithromycin", "suffix": " "}, {"to": "17677", "prefix": " MDZ dosing were used to estimate the effects of rifampin, ", "from": "17664", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC1865122.txt", "exact": "clarithromycin", "suffix": ", milk thistle, and black cohosh on CYP3A phenotype.\nDisinte"}, {"to": "20762", "prefix": "omplaints of a metallic taste were frequently noted during ", "from": "20749", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC1865122.txt", "exact": "clarithromycin", "suffix": " phases. Mild indigestion and reddish discoloration of the u"}, {"to": "21591", "prefix": "did not sleep or their sleep time was less than 0.5 hours. ", "from": "21578", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC1865122.txt", "exact": "Clarithromycin", "suffix": " increased the average sleep time for all subjects to 3"}, {"to": "21686", "prefix": "4 hours.\n\nThe effects of ", "from": "21673", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC1865122.txt", "exact": "clarithromycin", "suffix": ", rifampin, milk thistle, and black cohosh on serum MDZ conc"}, {"to": "22180", "prefix": "x, and elimination half-life were observed after 7 days of ", "from": "22167", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC1865122.txt", "exact": "clarithromycin", "suffix": " ingestion "}, {"to": "22227", "prefix": ". ", "from": "22214", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC1865122.txt", "exact": "Clarithromycin", "suffix": " also decreased MDZ apparent oral clearance by 88% "}, {"to": "22774", "prefix": ". In contrast to rifampin and ", "from": "22761", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC1865122.txt", "exact": "clarithromycin", "suffix": ", no significant changes in MDZ pharmacokinetics were observ"}, {"to": "23005", "prefix": "e 1\nMidazolam concentration-time profiles before and after ", "from": "22992", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC1865122.txt", "exact": "clarithromycin", "suffix": ". rifampin, milk thistle and black cohosh. Black squares "}, {"to": "23723", "prefix": "i.e. change in pre- versus post-", "from": "23710", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC1865122.txt", "exact": "clarithromycin", "suffix": " Cl"}, {"to": "24712", "prefix": ", while the opposite was true for ", "from": "24699", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC1865122.txt", "exact": "clarithromycin", "suffix": " treatment signifying CYP3A inhibition "}, {"to": "25294", "prefix": " ", "from": "25281", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC1865122.txt", "exact": "Clarithromycin", "suffix": ", "}, {"to": "26525", "prefix": " pharmacokinetics observed following the administration of ", "from": "26512", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC1865122.txt", "exact": "clarithromycin", "suffix": ", a known CYP3A4 inhibitor, and rifampin, a recognized induc"}, {"to": "27773", "prefix": "hibition, if any, was not comparable to that observed with ", "from": "27760", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC1865122.txt", "exact": "clarithromycin", "suffix": ".\n\nThe milk thistle product used in the present study was fo"}, {"to": "31521", "prefix": "orted here, and earlier,12 indicate that, when compared to ", "from": "31508", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC1865122.txt", "exact": "clarithromycin", "suffix": " and rifampin, recommended doses of black cohosh triterpene "}, {"to": "33663", "prefix": "ponse of CYP3A to induction by rifampin39 or inhibition by ", "from": "33650", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC1865122.txt", "exact": "clarithromycin", "suffix": ".40\n\nOur findings also support the utility of 1-hour HMDZ"}, {"to": "35738", "prefix": "n conclusion, when compared to the effects of rifampin and ", "from": "35725", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017291", "setId": "PMC1865122.txt", "exact": "clarithromycin", "suffix": ", the specific brand of milk thistle and black cohosh supple"}, {"to": "627", "prefix": "controls for CYP3A induction and inhibition, respectively. ", "from": "619", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC1865122.txt", "exact": "Midazolam", "suffix": " was administered orally before and after each supplementati"}, {"to": "794", "prefix": "ilk thistle, black cohosh, rifampin, and clarithromycin on ", "from": "786", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC1865122.txt", "exact": "midazolam", "suffix": " pharmacokinetics were determined using noncompartmental tec"}, {"to": "927", "prefix": "es. Unlike those observed for rifampin and clarithromycin, ", "from": "919", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC1865122.txt", "exact": "midazolam", "suffix": " pharmacokinetics were unaffected by milk thistle or black c"}, {"to": "3297", "prefix": "rlic powder on the pharmacokinetics of orally administered ", "from": "3289", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC1865122.txt", "exact": "midazolam", "suffix": ", a recognized CYP3A4"}, {"to": "5918", "prefix": "36 However, for ", "from": "5910", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC1865122.txt", "exact": "midazolam", "suffix": " "}, {"to": "6019", "prefix": "", "from": "6011", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC1865122.txt", "exact": "midazolam", "suffix": " ratios to predict midazolam clearance.37,38 In this report "}, {"to": "6047", "prefix": "midazolam ratios to predict ", "from": "6039", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC1865122.txt", "exact": "midazolam", "suffix": " clearance.37,38 In this report we describe, for the first t"}, {"to": "6209", "prefix": "nd black cohosh supplementation on the pharmacokinetics of ", "from": "6201", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC1865122.txt", "exact": "midazolam", "suffix": ", a recognized CYP3A4 substrate. In addition, we compare the"}, {"to": "7493", "prefix": "these restrictions was further emphasized five days before ", "from": "7485", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC1865122.txt", "exact": "midazolam", "suffix": " administration. Subjects were also instructed to refrain fr"}, {"to": "7938", "prefix": "milk thistle, black cohosh, rifampin and clarithromycin on ", "from": "7930", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC1865122.txt", "exact": "midazolam", "suffix": " pharmacokinetics was evaluated individually on four separat"}, {"to": "9562", "prefix": "lementation usage records, were used to verify compliance.\n", "from": "9554", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC1865122.txt", "exact": "Midazolam", "suffix": " administration\n\nFollowing an overnight fast, subjects repor"}, {"to": "9723", "prefix": " for Medical Sciences General Clinical Research Center for ", "from": "9715", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC1865122.txt", "exact": "midazolam", "suffix": " administration and blood sampling. Prior to midazolam admin"}, {"to": "9777", "prefix": " for midazolam administration and blood sampling. Prior to ", "from": "9769", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC1865122.txt", "exact": "midazolam", "suffix": " administration subjects were weighed and questioned about t"}, {"to": "10140", "prefix": "ter into a peripheral vein of the forearm, an oral dose of ", "from": "10132", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC1865122.txt", "exact": "midazolam", "suffix": " "}, {"to": "10253", "prefix": "s administered with 240 ml of water. Throughout the study, ", "from": "10245", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC1865122.txt", "exact": "midazolam", "suffix": " doses were administered 24 hours before the start of each s"}, {"to": "10511", "prefix": "at 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, and 6 hours after ", "from": "10503", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC1865122.txt", "exact": "midazolam", "suffix": " administration. Blood samples were allowed to clot for 30 m"}, {"to": "10802", "prefix": "respiration rate was monitored at 0.5, 1, and 2 hours post-", "from": "10794", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC1865122.txt", "exact": "midazolam", "suffix": " administration. Four hours after dosing, subjects received "}, {"to": "10977", "prefix": ", potato chips, carrot sticks, and water.\nDetermination of ", "from": "10969", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC1865122.txt", "exact": "midazolam", "suffix": " "}, {"to": "17111", "prefix": "ke. The apparent oral clearance of ", "from": "17103", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC1865122.txt", "exact": "midazolam", "suffix": " "}, {"to": "17805", "prefix": "gration tests\n\nAn absence of botanical-mediated effects on ", "from": "17797", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC1865122.txt", "exact": "midazolam", "suffix": " pharmacokinetics could stem from products exhibiting poor d"}, {"to": "22945", "prefix": ".\nFigure 1\nFigure 1\n", "from": "22937", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC1865122.txt", "exact": "Midazolam", "suffix": " concentration-time profiles before and after clarithromycin"}, {"to": "23195", "prefix": " standard deviations.\nTable I\nTable I\n", "from": "23187", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC1865122.txt", "exact": "Midazolam", "suffix": " pharmacokinetic parameters before and after supplementation"}, {"to": "25248", "prefix": "", "from": "25240", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC1865122.txt", "exact": "midazolam", "suffix": ""}, {"to": "25487", "prefix": "", "from": "25479", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC1865122.txt", "exact": "midazolam", "suffix": " phenotypic ratios versus midazolam oral clearance "}, {"to": "25522", "prefix": "midazolam phenotypic ratios versus ", "from": "25514", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC1865122.txt", "exact": "midazolam", "suffix": " oral clearance "}, {"to": "35890", "prefix": "tudy produced no significant changes in the disposition of ", "from": "35882", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "PMC1865122.txt", "exact": "midazolam", "suffix": ", a clinically recognized CYP3A substrate. Accordingly, thes"}, {"to": "2016", "prefix": "s wort can be traced to ", "from": "2007", "name": "hyperforin", "fullId": "http://purl.bioontology.org/ontology/MESH/C001654", "setId": "PMC1865122.txt", "exact": "hyperforin", "suffix": ", a phytochemical component of H. perforatum and a potent li"}, {"to": "3018", "prefix": "cal. Piscitelli et al. observed a significant reduction in ", "from": "3009", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83395", "setId": "PMC1865122.txt", "exact": "saquinavir", "suffix": " area-under-the-curve when garlic powder was administered co"}, {"to": "3428", "prefix": "stle appeared to have no effect on the pharmacokinetics of ", "from": "3420", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "PMC1865122.txt", "exact": "indinavir", "suffix": ", a substrate for CYP3A4 and P-gp;19"}, {"to": "30162", "prefix": "atistically significant changes in the pharmacokinetics of ", "from": "30154", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "PMC1865122.txt", "exact": "indinavir", "suffix": ", a CYP3A"}, {"to": "30240", "prefix": " in ", "from": "30232", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "PMC1865122.txt", "exact": "indinavir", "suffix": " AUC were noted in each study. Collectively, the above studi"}, {"to": "3504", "prefix": "21 however, its effect on ", "from": "3492", "name": "Metronidazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D008795", "setId": "PMC1865122.txt", "exact": "metronidazole", "suffix": ", another putative CYP3A"}, {"to": "29834", "prefix": " increased the clearance of ", "from": "29822", "name": "Metronidazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D008795", "setId": "PMC1865122.txt", "exact": "metronidazole", "suffix": ", a substrate of CYP2C9, CYP3A, and P-gp, by almost 30%.22 T"}, {"to": "4490", "prefix": " which include ", "from": "4482", "name": "silybin", "fullId": "http://purl.bioontology.org/ontology/MESH/C440975", "setId": "PMC1865122.txt", "exact": "silibinin", "suffix": " A, silibinin B, silidianin, silichristin, and taxifolin. Re"}, {"to": "4503", "prefix": " which include silibinin A, ", "from": "4495", "name": "silybin", "fullId": "http://purl.bioontology.org/ontology/MESH/C440975", "setId": "PMC1865122.txt", "exact": "silibinin", "suffix": " B, silidianin, silichristin, and taxifolin. Recent in vitro"}, {"to": "14022", "prefix": "of the flavanolignans taxifolin, silychristin, silydianin, ", "from": "14014", "name": "silybin", "fullId": "http://purl.bioontology.org/ontology/MESH/C440975", "setId": "PMC1865122.txt", "exact": "silibinin", "suffix": " A, and silibinin B were purchased from ChromaDex, Inc. "}, {"to": "14039", "prefix": "nans taxifolin, silychristin, silydianin, silibinin A, and ", "from": "14031", "name": "silybin", "fullId": "http://purl.bioontology.org/ontology/MESH/C440975", "setId": "PMC1865122.txt", "exact": "silibinin", "suffix": " B were purchased from ChromaDex, Inc. "}, {"to": "15501", "prefix": ". Retention times for taxifolin, silichristin, silidianin, ", "from": "15493", "name": "silybin", "fullId": "http://purl.bioontology.org/ontology/MESH/C440975", "setId": "PMC1865122.txt", "exact": "silibinin", "suffix": " A, and silibinin B were 9.6, 16.5, 18.8, 23.7 and 24.7 minu"}, {"to": "15518", "prefix": " for taxifolin, silichristin, silidianin, silibinin A, and ", "from": "15510", "name": "silybin", "fullId": "http://purl.bioontology.org/ontology/MESH/C440975", "setId": "PMC1865122.txt", "exact": "silibinin", "suffix": " B were 9.6, 16.5, 18.8, 23.7 and 24.7 minutes, respectively"}, {"to": "26708", "prefix": "i.e., ", "from": "26700", "name": "silybin", "fullId": "http://purl.bioontology.org/ontology/MESH/C440975", "setId": "PMC1865122.txt", "exact": "silibinin", "suffix": " A, silibinin B silidianin, silichristin, and taxifolin"}, {"to": "26721", "prefix": "i.e., silibinin A, ", "from": "26713", "name": "silybin", "fullId": "http://purl.bioontology.org/ontology/MESH/C440975", "setId": "PMC1865122.txt", "exact": "silibinin", "suffix": " B silidianin, silichristin, and taxifolin"}, {"to": "27397", "prefix": "30 with some evidence that ", "from": "27389", "name": "silybin", "fullId": "http://purl.bioontology.org/ontology/MESH/C440975", "setId": "PMC1865122.txt", "exact": "silibinin", "suffix": " can act as a mechanism-based inhibitor of CYP3A.26 From the"}, {"to": "28347", "prefix": "ne separate milk thistle products found that the amount of ", "from": "28339", "name": "silybin", "fullId": "http://purl.bioontology.org/ontology/MESH/C440975", "setId": "PMC1865122.txt", "exact": "silibinin", "suffix": " released over one hour into an aqueous buffered solution "}, {"to": "28501", "prefix": "85%;45 while a comparative bioavailability study of three ", "from": "28493", "name": "silybin", "fullId": "http://purl.bioontology.org/ontology/MESH/C440975", "setId": "PMC1865122.txt", "exact": "silibinin", "suffix": "-containing dosage forms found that values for AUC and Cmax "}, {"to": "28986", "prefix": "haracteristics of silymarin is significantly enhanced when ", "from": "28978", "name": "silybin", "fullId": "http://purl.bioontology.org/ontology/MESH/C440975", "setId": "PMC1865122.txt", "exact": "silibinin", "suffix": " is complexed with phosphotidylcholine or formulated as lipi"}, {"to": "4517", "prefix": " which include silibinin A, silibinin B, ", "from": "4508", "name": "silydianin", "fullId": "http://purl.bioontology.org/ontology/MESH/C015505", "setId": "PMC1865122.txt", "exact": "silidianin", "suffix": ", silichristin, and taxifolin. Recent in vitro studies indic"}, {"to": "14011", "prefix": "l standards of the flavanolignans taxifolin, silychristin, ", "from": "14002", "name": "silydianin", "fullId": "http://purl.bioontology.org/ontology/MESH/C015505", "setId": "PMC1865122.txt", "exact": "silydianin", "suffix": ", silibinin A, and silibinin B were purchased from ChromaDex"}, {"to": "15490", "prefix": "gth of 290nm. Retention times for taxifolin, silichristin, ", "from": "15481", "name": "silydianin", "fullId": "http://purl.bioontology.org/ontology/MESH/C015505", "setId": "PMC1865122.txt", "exact": "silidianin", "suffix": ", silibinin A, and silibinin B were 9.6, 16.5, 18.8, 23.7 an"}, {"to": "26734", "prefix": "i.e., silibinin A, silibinin B ", "from": "26725", "name": "silydianin", "fullId": "http://purl.bioontology.org/ontology/MESH/C015505", "setId": "PMC1865122.txt", "exact": "silidianin", "suffix": ", silichristin, and taxifolin"}, {"to": "4546", "prefix": "de silibinin A, silibinin B, silidianin, silichristin, and ", "from": "4538", "name": "taxifolin", "fullId": "http://purl.bioontology.org/ontology/MESH/C003377", "setId": "PMC1865122.txt", "exact": "taxifolin", "suffix": ". Recent in vitro studies indicate that both silymarin and i"}, {"to": "13985", "prefix": " by HPLC. Analytical standards of the flavanolignans ", "from": "13977", "name": "taxifolin", "fullId": "http://purl.bioontology.org/ontology/MESH/C003377", "setId": "PMC1865122.txt", "exact": "taxifolin", "suffix": ", silychristin, silydianin, silibinin A, and silibinin B wer"}, {"to": "15464", "prefix": " at a wavelength of 290nm. Retention times for ", "from": "15456", "name": "taxifolin", "fullId": "http://purl.bioontology.org/ontology/MESH/C003377", "setId": "PMC1865122.txt", "exact": "taxifolin", "suffix": ", silichristin, silidianin, silibinin A, and silibinin B wer"}, {"to": "26763", "prefix": "e., silibinin A, silibinin B silidianin, silichristin, and ", "from": "26755", "name": "taxifolin", "fullId": "http://purl.bioontology.org/ontology/MESH/C003377", "setId": "PMC1865122.txt", "exact": "taxifolin", "suffix": ""}, {"to": "4600", "prefix": " and taxifolin. Recent in vitro studies indicate that both ", "from": "4592", "name": "Silymarin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9794", "setId": "PMC1865122.txt", "exact": "silymarin", "suffix": " and individual flavanolignans may function as substrates an"}, {"to": "9228", "prefix": "300 mg, three times daily, standardized to contain 80% ", "from": "9220", "name": "Silymarin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9794", "setId": "PMC1865122.txt", "exact": "silymarin", "suffix": ""}, {"to": "15694", "prefix": "mL. The interday accuracy and precision for ", "from": "15686", "name": "Silymarin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9794", "setId": "PMC1865122.txt", "exact": "silymarin", "suffix": " components at 0.05, 0.1, and 0.5 "}, {"to": "25845", "prefix": " these findings, subjects ingested approximately 440 mg of ", "from": "25837", "name": "Silymarin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9794", "setId": "PMC1865122.txt", "exact": "silymarin", "suffix": " and 3.0 mg of triterpene glycosides on a daily basis. In ad"}, {"to": "26691", "prefix": "our results do not support previous in vitro findings that ", "from": "26683", "name": "Silymarin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9794", "setId": "PMC1865122.txt", "exact": "silymarin", "suffix": " "}, {"to": "27062", "prefix": "hat in vitro studies demonstrating an inhibitory effect of ", "from": "27054", "name": "Silymarin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9794", "setId": "PMC1865122.txt", "exact": "silymarin", "suffix": " on CYP3A4 activity have utilized solubilizing agents "}, {"to": "27322", "prefix": "del utilized, IC50 values for individual flavanolignans or ", "from": "27314", "name": "Silymarin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9794", "setId": "PMC1865122.txt", "exact": "silymarin", "suffix": " extract have ranged from 25"}, {"to": "27524", "prefix": "e results of the present study, it would appear that local ", "from": "27516", "name": "Silymarin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9794", "setId": "PMC1865122.txt", "exact": "silymarin", "suffix": " concentrations at intestinal enterocyte membrane interfaces"}, {"to": "28207", "prefix": "eless, bioavailability and dissolution characteristics for ", "from": "28199", "name": "Silymarin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9794", "setId": "PMC1865122.txt", "exact": "silymarin", "suffix": "-containing products have been shown to vary widely. An eval"}, {"to": "28680", "prefix": "tively.46 Moreover, several studies have demonstrated that ", "from": "28672", "name": "Silymarin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9794", "setId": "PMC1865122.txt", "exact": "silymarin", "suffix": "-containing products exhibit especially poor bioavailability"}, {"to": "28945", "prefix": "49 The bioavailability and drug-release characteristics of ", "from": "28937", "name": "Silymarin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9794", "setId": "PMC1865122.txt", "exact": "silymarin", "suffix": " is significantly enhanced when silibinin is complexed with "}, {"to": "29767", "prefix": " CYP3A substrates. Rajnarayana et al. found that 9 days of ", "from": "29759", "name": "Silymarin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9794", "setId": "PMC1865122.txt", "exact": "silymarin", "suffix": " administration "}, {"to": "30356", "prefix": " above studies hint at a possible mild inductive effect of ", "from": "30348", "name": "Silymarin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9794", "setId": "PMC1865122.txt", "exact": "silymarin", "suffix": " on CYP3A and"}, {"to": "30618", "prefix": "f CYP3A transfected in HepG2 cells, found no evidence that ", "from": "30610", "name": "Silymarin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9794", "setId": "PMC1865122.txt", "exact": "silymarin", "suffix": ", when solubilized with dimethylsulfoxide "}, {"to": "30930", "prefix": " implying that conventional ", "from": "30922", "name": "Silymarin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9794", "setId": "PMC1865122.txt", "exact": "silymarin", "suffix": " formulations are devoid of any clinically relevant CYP3A mo"}, {"to": "5712", "prefix": "14,33 For probe drugs like ", "from": "5705", "name": "Caffeine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002110", "setId": "PMC1865122.txt", "exact": "caffeine", "suffix": " "}, {"to": "7306", "prefix": "ine. All subjects were instructed to abstain from alcohol, ", "from": "7299", "name": "Caffeine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002110", "setId": "PMC1865122.txt", "exact": "caffeine", "suffix": ", fruit juices, cruciferous vegetables, and charbroiled meat"}, {"to": "5741", "prefix": ", ", "from": "5730", "name": "Debrisoquin", "fullId": "http://purl.bioontology.org/ontology/MESH/D003647", "setId": "PMC1865122.txt", "exact": "debrisoquine", "suffix": " "}, {"to": "5775", "prefix": ", and ", "from": "5763", "name": "Chlorzoxazone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2410", "setId": "PMC1865122.txt", "exact": "chlorzoxazone", "suffix": " "}, {"to": "11539", "prefix": "L of 0.2M ", "from": "11526", "name": "Sodium Acetate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/56443", "setId": "PMC1865122.txt", "exact": "sodium acetate", "suffix": " "}, {"to": "12178", "prefix": "lumns and washed with 2 mL of 0.1% H3PO4 in 50:50 methanol:", "from": "12167", "name": "acetonitrile", "fullId": "http://purl.bioontology.org/ontology/MESH/C032159", "setId": "PMC1865122.txt", "exact": "acetonitrile", "suffix": " followed by 1 mL of 50:50 methanol:acetonitrile. MDZ and HM"}, {"to": "12226", "prefix": "0 methanol:acetonitrile followed by 1 mL of 50:50 methanol:", "from": "12215", "name": "acetonitrile", "fullId": "http://purl.bioontology.org/ontology/MESH/C032159", "setId": "PMC1865122.txt", "exact": "acetonitrile", "suffix": ". MDZ and HMDZ were eluted by gravity flow using 3 mL 6% amm"}, {"to": "12321", "prefix": "ed by gravity flow using 3 mL 6% ammonia in 50:50 methanol:", "from": "12310", "name": "acetonitrile", "fullId": "http://purl.bioontology.org/ontology/MESH/C032159", "setId": "PMC1865122.txt", "exact": "acetonitrile", "suffix": ". Eluents were dried under nitrogen and reconstituted in 75 "}, {"to": "12422", "prefix": "30% ", "from": "12411", "name": "acetonitrile", "fullId": "http://purl.bioontology.org/ontology/MESH/C032159", "setId": "PMC1865122.txt", "exact": "acetonitrile", "suffix": ", 5mM ammonium formate pH 3.0"}, {"to": "12860", "prefix": "min using a 4-min. linear gradient from 30% to 80% ", "from": "12849", "name": "acetonitrile", "fullId": "http://purl.bioontology.org/ontology/MESH/C032159", "setId": "PMC1865122.txt", "exact": "acetonitrile", "suffix": ":ammonium formate "}, {"to": "13999", "prefix": "PLC. Analytical standards of the flavanolignans taxifolin, ", "from": "13988", "name": "silychristin", "fullId": "http://purl.bioontology.org/ontology/MESH/C015504", "setId": "PMC1865122.txt", "exact": "silychristin", "suffix": ", silydianin, silibinin A, and silibinin B were purchased fr"}, {"to": "14455", "prefix": "n individual brown glass bottles and dissolved in 75 mL of ", "from": "14449", "name": "Ethanol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/448", "setId": "PMC1865122.txt", "exact": "ethanol", "suffix": ". The contents of each vessel were agitated at 75 rpm for 4 "}, {"to": "27882", "prefix": "esent study was formulated with soybean oil, glycerin, and ", "from": "27875", "name": "Lecithin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8214", "setId": "PMC1865122.txt", "exact": "lecithin", "suffix": " in a soft gelatin capsule, and upon disintegration the cont"}, {"to": "27900", "prefix": "mulated with soybean oil, glycerin, and lecithin in a soft ", "from": "27894", "name": "Gelatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4716", "setId": "PMC1865122.txt", "exact": "gelatin", "suffix": " capsule, and upon disintegration the contents appeared to r"}, {"to": "28870", "prefix": "h solubility-enhancing agents like phosphatidylcholine and ", "from": "28852", "name": "Polyethylene Glycols", "fullId": "http://purl.bioontology.org/ontology/MESH/D011092", "setId": "PMC1865122.txt", "exact": "polyethylene glycol", "suffix": ".45,47"}, {"to": "30659", "prefix": "s, found no evidence that silymarin, when solubilized with ", "from": "30643", "name": "Dimethyl Sulfoxide", "fullId": "http://purl.bioontology.org/ontology/MESH/D004121", "setId": "PMC1865122.txt", "exact": "dimethylsulfoxide", "suffix": " "}, {"to": "30665", "prefix": "", "from": "30662", "name": "Dimethyl Sulfoxide", "fullId": "http://purl.bioontology.org/ontology/MESH/D004121", "setId": "PMC1865122.txt", "exact": "DMSO", "suffix": ""}, {"to": "31343", "prefix": "ent in vitro findings demonstrate that, in the presence of ", "from": "31340", "name": "Dimethyl Sulfoxide", "fullId": "http://purl.bioontology.org/ontology/MESH/D004121", "setId": "PMC1865122.txt", "exact": "DMSO", "suffix": ", black cohosh extracts or individual triterpene glycosides "}, {"to": "32939", "prefix": " two phytochemicals primarily responsible for this effect, ", "from": "32929", "name": "bergamottin", "fullId": "http://purl.bioontology.org/ontology/MESH/C068337", "setId": "PMC1865122.txt", "exact": "bergamottin", "suffix": " and 6"}, {"to": "42", "prefix": "Abstract\nAims\n\nThe effects of ", "from": "31", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " on the pharmacokinetics of fluvastatin and lovastatin, two "}, {"to": "415", "prefix": "identical in both studies. The subjects took either 100 mg ", "from": "404", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " or matched placebo orally once daily for 4 days. On day 4, "}, {"to": "617", "prefix": "oncentrations of fluvastatin, lovastatin, lovastatin acid, ", "from": "606", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " and hydroxyitraconazole were determined up to 24 h.\nResults"}, {"to": "691", "prefix": "d hydroxyitraconazole were determined up to 24 h.\nResults\n\n", "from": "680", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "Itraconazole", "suffix": " had no significant effect on the Cmax "}, {"to": "943", "prefix": "2,z of fluvastatin was slightly prolonged by ", "from": "932", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " "}, {"to": "1100", "prefix": " by ", "from": "1089", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": ". Similarly, the Cmax and total AUC of lovastatin acid were "}, {"to": "1281", "prefix": " by ", "from": "1270", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": ", respectively. The t1"}, {"to": "1402", "prefix": "4.0 h during the ", "from": "1391", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " phase; these variables could not be determined in all subje"}, {"to": "1517", "prefix": "ned in all subjects during the placebo phase.\nConclusions\n\n", "from": "1506", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "Itraconazole", "suffix": ", even at a small dosage of 100 mg daily, greatly elevated p"}, {"to": "1727", "prefix": "Lovastatin should therefore not be used concomitantly with ", "from": "1716", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " and other potent CYP3A4 inhibitors, or the dosage of lovast"}, {"to": "1938", "prefix": "astatin concentrations were not significantly increased by ", "from": "1927", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": ", indicating that fluvastatin has much less potential than l"}, {"to": "2065", "prefix": "an lovastatin for clinically significant interactions with ", "from": "2054", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " and other CYP3A4 inhibitors.\nKeywords: fluvastatin, interac"}, {"to": "2143", "prefix": "her CYP3A4 inhibitors.\nKeywords: fluvastatin, interaction, ", "from": "2132", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": ", lovastatin, pharmacokinetics\nGo to:\nIntroduction\n\nFluvasta"}, {"to": "2900", "prefix": "lovastatin and, for example, cyclosporine, erythromycin or ", "from": "2889", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " is associated with a considerably increased risk of skeleta"}, {"to": "3337", "prefix": "aim of the present study was to characterize the effect of ", "from": "3326", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " on the pharmacokinetics of fluvastatin and, in particular, "}, {"to": "3511", "prefix": " is less liable to interact with CYP3A4 inhibitors such as ", "from": "3500", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " than lovastatin.\nGo to:\nMethods\nSubjects\n\nTen healthy volun"}, {"to": "4515", "prefix": "cal in both studies. The subjects were given either 100 mg ", "from": "4504", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " "}, {"to": "4893", "prefix": "h 150 ml water at 09.00 h, i.e. 1 h after the last dose of ", "from": "4882", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": ". The subjects fasted for 1 h before administration of fluva"}, {"to": "6763", "prefix": ".\n\nTo assess the comparability of plasma ", "from": "6752", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " and hydroxyitraconazole levels between the lovastatin and f"}, {"to": "6862", "prefix": "els between the lovastatin and fluvastatin studies, plasma ", "from": "6851", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " and hydroxyitraconazole concentrations were determined in a"}, {"to": "6975", "prefix": "re determined in all samples, i.e. from 1 h after the last ", "from": "6964", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " dose on day 4 up to 25 h. Itraconazole and hydroxyitraconaz"}, {"to": "7014", "prefix": " 1 h after the last itraconazole dose on day 4 up to 25 h. ", "from": "7003", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "Itraconazole", "suffix": " and hydroxyitraconazole concentrations were determined by h"}, {"to": "7319", "prefix": " for ", "from": "7308", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " and 3.7% "}, {"to": "8380", "prefix": "e placebo phase due to low plasma drug concentrations. For ", "from": "8369", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " and hydroxyitraconazole, the AUC "}, {"to": "8722", "prefix": "", "from": "8711", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " and placebo"}, {"to": "9051", "prefix": "0.05.\nGo to:\nResults\nFluvastatin\n\nPretreatment with ", "from": "9040", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " had no significant effect on the Cmax "}, {"to": "9268", "prefix": ". The total AUC of fluvastatin during the ", "from": "9257", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " phase relative to that during the placebo phase averaged 1."}, {"to": "9416", "prefix": "2,z of fluvastatin was slightly prolonged by ", "from": "9405", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " "}, {"to": "9620", "prefix": "fter a 40 mg oral dose, following pretreatment with 100 mg ", "from": "9609", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " "}, {"to": "9926", "prefix": ", following pretreatment with placebo or 100 mg ", "from": "9915", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " once daily for 4 days. ...\nLovastatin and lovastatin acid\n\n"}, {"to": "9998", "prefix": "once daily for 4 days. ...\nLovastatin and lovastatin acid\n\n", "from": "9987", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "Itraconazole", "suffix": " considerably increased the plasma concentrations of both lo"}, {"to": "10251", "prefix": " by ", "from": "10240", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": ". The t1"}, {"to": "10320", "prefix": "3.8 h during the ", "from": "10309", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " phase, but during the placebo phase it could be determined "}, {"to": "10675", "prefix": "ral dose of lovastatin, following pretreatment with 100 mg ", "from": "10664", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " "}, {"to": "10913", "prefix": " by ", "from": "10902", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": ", respectively. The t1"}, {"to": "10996", "prefix": "4.0 h during the ", "from": "10985", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " phase; in the placebo phase, it could be determined in only"}, {"to": "11101", "prefix": "ould be determined in only five subjects, averaging 6.1 h.\n", "from": "11090", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "Itraconazole", "suffix": " and hydroxyitraconazole\n\nThe mean plasma concentrations of "}, {"to": "11173", "prefix": "and hydroxyitraconazole\n\nThe mean plasma concentrations of ", "from": "11162", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " and its active metabolite hydroxyitraconazole on the day of"}, {"to": "11330", "prefix": " of ", "from": "11319", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " was 1921"}, {"to": "11582", "prefix": " of ", "from": "11571", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " or hydroxyitraconazole between the two studies.\nFigure 3\nFi"}, {"to": "11686", "prefix": "he two studies.\nFigure 3\nFigure 3\nPlasma concentrations of ", "from": "11675", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " "}, {"to": "11886", "prefix": " after intake of 100 mg ", "from": "11875", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " orally once daily ...\nGo to:\nDiscussion\n\nThe results of thi"}, {"to": "12124", "prefix": "atin acid, are greatly increased by a daily dose of 100 mg ", "from": "12113", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": ". By contrast, itraconazole had no significant effect on pla"}, {"to": "12151", "prefix": "eased by a daily dose of 100 mg itraconazole. By contrast, ", "from": "12140", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " had no significant effect on plasma fluvastatin concentrati"}, {"to": "12292", "prefix": "er, the half-life of fluvastatin was slightly prolonged by ", "from": "12281", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": ", but this should not have any clinical relevance. The incre"}, {"to": "12407", "prefix": "vance. The increase in the total AUC of lovastatin acid by ", "from": "12396", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " was, on an average, 15-fold, but showed marked interindivid"}, {"to": "12494", "prefix": "age, 15-fold, but showed marked interindividual variation. ", "from": "12483", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "Itraconazole", "suffix": " appeared to have a similar effect on the total AUC of lovas"}, {"to": "13239", "prefix": "n acid is not dependent on CYP3A4, inhibition of CYP3A4 by ", "from": "13228", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " results in greatly elevated plasma lovastatin concentration"}, {"to": "13742", "prefix": "f lovastatin and lovastatin acid were greatly increased by ", "from": "13731", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": ", with only a minor effect on their t1"}, {"to": "13952", "prefix": ", it is likely that the interaction between lovastatin and ", "from": "13941", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " results mainly from inhibition of the CYP3A4-mediated first"}, {"to": "14104", "prefix": "ovastatin.\n\nIn a previous study, a 4-day pretreatment with ", "from": "14093", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": ", 200 mg daily, increased the AUC of lovastatin and lovastat"}, {"to": "14270", "prefix": "of the present study was to evaluate the effect of a lower ", "from": "14259", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " dosage, 100 mg daily, on lovastatin pharmacokinetics. Altho"}, {"to": "14356", "prefix": " daily, on lovastatin pharmacokinetics. Although the lower ", "from": "14345", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " dosage appeared to have a slightly smaller effect on the pl"}, {"to": "14598", "prefix": "raction with lovastatin.\n\nConsidering the marked effect of ", "from": "14587", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " 100 mg daily on plasma lovastatin and lovastatin acid conce"}, {"to": "14844", "prefix": "tion would occur between fluvastatin and higher dosages of ", "from": "14833", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": ". In a recent study, AUC values for fluvastatin were about 2"}, {"to": "15474", "prefix": " noted that apart from inhibiting CYP3A4, cyclosporine and ", "from": "15463", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " may increase plasma concentrations of HMG-CoA reductase inh"}, {"to": "15912", "prefix": "se of rhabdomyolysis occurring in a patient receiving both ", "from": "15901", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " "}, {"to": "16355", "prefix": "fore be expected that simvastatin would also interact with ", "from": "16344", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " and other potent CYP3A4 inhibitors to a clinically signific"}, {"to": "16530", "prefix": "rts indicate that concomitant therapy with simvastatin and ", "from": "16519", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": ", cyclosporine or other CYP3A4 inhibitors predisposes to myo"}, {"to": "16766", "prefix": "t simvastatin acid concentrations are greatly increased by ", "from": "16755", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " [21].\n\nIn conclusion, the results of this study indicate th"}, {"to": "16841", "prefix": "].\n\nIn conclusion, the results of this study indicate that ", "from": "16830", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": ", even at a dosage of 100 mg daily, greatly elevates plasma "}, {"to": "17243", "prefix": "astatin concentrations were not significantly increased by ", "from": "17232", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": ", indicating that fluvastatin has much less potential than l"}, {"to": "17370", "prefix": "an lovastatin for clinically significant interactions with ", "from": "17359", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1873980.txt", "exact": "itraconazole", "suffix": " and other CYP3A4 inhibitors.\nGo to:\nAcknowledgments\n\nThe sk"}, {"to": "4525", "prefix": "", "from": "4518", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D017964", "setId": "PMC1873980.txt", "exact": "Sporanox", "suffix": ", Janssen, Beerse, Belgium"}, {"to": "81", "prefix": "ms\n\nThe effects of itraconazole on the pharmacokinetics of ", "from": "71", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " and lovastatin, two inhibitors of HMG-CoA reductase with di"}, {"to": "492", "prefix": "ched placebo orally once daily for 4 days. On day 4, 40 mg ", "from": "482", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " or 40 mg lovastatin was administered orally. Plasma concent"}, {"to": "574", "prefix": "vastatin was administered orally. Plasma concentrations of ", "from": "564", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": ", lovastatin, lovastatin acid, itraconazole and hydroxyitrac"}, {"to": "846", "prefix": " of ", "from": "836", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " compared with placebo. However, the t1"}, {"to": "904", "prefix": "2,z of ", "from": "894", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " was slightly prolonged by itraconazole "}, {"to": "1874", "prefix": "eatly reduced while using a CYP3A4 inhibitor. In contrast, ", "from": "1864", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " concentrations were not significantly increased by itracona"}, {"to": "1967", "prefix": "t significantly increased by itraconazole, indicating that ", "from": "1957", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " has much less potential than lovastatin for clinically sign"}, {"to": "2116", "prefix": "s with itraconazole and other CYP3A4 inhibitors.\nKeywords: ", "from": "2106", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": ", interaction, itraconazole, lovastatin, pharmacokinetics\nGo"}, {"to": "2206", "prefix": "onazole, lovastatin, pharmacokinetics\nGo to:\nIntroduction\n\n", "from": "2196", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "Fluvastatin", "suffix": " and lovastatin are inhibitors of 3-hydroxy-3-methylglutaryl"}, {"to": "2674", "prefix": " primarily mediated by CYP3A4 [2]. The pharmacokinetics of ", "from": "2664", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " differ considerably from those of lovastatin; fluvastatin i"}, {"to": "2732", "prefix": " fluvastatin differ considerably from those of lovastatin; ", "from": "2722", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " is not a pro-drug and it appears to be metabolized mainly b"}, {"to": "3376", "prefix": "rize the effect of itraconazole on the pharmacokinetics of ", "from": "3366", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " and, in particular, to evaluate the hypothesis that fluvast"}, {"to": "3440", "prefix": "statin and, in particular, to evaluate the hypothesis that ", "from": "3430", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " is less liable to interact with CYP3A4 inhibitors such as i"}, {"to": "3608", "prefix": "thods\nSubjects\n\nTen healthy volunteers participated in the ", "from": "3598", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " study "}, {"to": "4235", "prefix": "re using oral contraceptive steroids in the lovastatin and ", "from": "4225", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " studies, respectively.\nStudy design\n\nTwo separate randomize"}, {"to": "4640", "prefix": "o orally once daily at 08.00 h for 4 days. On day 4, 40 mg ", "from": "4630", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " "}, {"to": "4959", "prefix": "zole. The subjects fasted for 1 h before administration of ", "from": "4949", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " or lovastatin. A warm standard meal was served 4 h and a li"}, {"to": "5058", "prefix": "rd meal was served 4 h and a light standard meal 8 h after ", "from": "5048", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " or lovastatin intake. The subjects were not allowed to drin"}, {"to": "5526", "prefix": " cannulated and timed blood samples were drawn just before ", "from": "5516", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " or lovastatin was administered and 0.5, 1, 2, 3, 4, 6, 8, 1"}, {"to": "6383", "prefix": " for lovastatin acid.\n\n", "from": "6373", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "Fluvastatin", "suffix": " concentrations were determined by h.p.l.c. using automated "}, {"to": "6542", "prefix": "uorescence detection [11]. The limit of quantification for ", "from": "6532", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " was 0.4 ng ml"}, {"to": "6593", "prefix": "1. The within-day CV for ", "from": "6583", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " was 4.3% at 0.49 ng ml"}, {"to": "6833", "prefix": " and hydroxyitraconazole levels between the lovastatin and ", "from": "6823", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " studies, plasma itraconazole and hydroxyitraconazole concen"}, {"to": "7533", "prefix": ".\nPharmacokinetics\n\nThe pharmacokinetics of ", "from": "7523", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": ", lovastatin and lovastatin acid were characterized, as appr"}, {"to": "9019", "prefix": "0.05.\nGo to:\nResults\n", "from": "9009", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "Fluvastatin", "suffix": "\n\nPretreatment with itraconazole had no significant effect o"}, {"to": "9194", "prefix": " of ", "from": "9184", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " "}, {"to": "9244", "prefix": ". The total AUC of ", "from": "9234", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " during the itraconazole phase relative to that during the p"}, {"to": "9377", "prefix": "2,z of ", "from": "9367", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " was slightly prolonged by itraconazole "}, {"to": "9505", "prefix": ".\nFigure 1\nFigure 1\nPlasma concentrations of ", "from": "9495", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " in 10 healthy volunteers "}, {"to": "9747", "prefix": "r 4 days.\nTable 1\nTable 1\nThe pharmacokinetic variables of ", "from": "9737", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " 40 mg "}, {"to": "11245", "prefix": "nd its active metabolite hydroxyitraconazole on the day of ", "from": "11235", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " or lovastatin administration are shown in Figure 3. The AUC"}, {"to": "11372", "prefix": "1 h in the ", "from": "11362", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " study and 2018"}, {"to": "11713", "prefix": "open circles, ", "from": "11703", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " study; closed circles, lovastatin study"}, {"to": "11807", "prefix": "open triangles, ", "from": "11797", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " study; closed triangles, lovastatin study"}, {"to": "12199", "prefix": "contrast, itraconazole had no significant effect on plasma ", "from": "12189", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " concentrations. However, the half-life of fluvastatin was s"}, {"to": "12253", "prefix": "asma fluvastatin concentrations. However, the half-life of ", "from": "12243", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " was slightly prolonged by itraconazole, but this should not"}, {"to": "12840", "prefix": "h the knowledge of the biotransformation of lovastatin and ", "from": "12830", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": ". The pro-drug lovastatin is partly hydrolysed to the active"}, {"to": "13395", "prefix": "ing increase in lovastatin acid levels. Unlike lovastatin, ", "from": "13385", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " seems to be metabolized primarily by CYP2C9; CYP3A4 does no"}, {"to": "13495", "prefix": "rily by CYP2C9; CYP3A4 does not play a significant role in ", "from": "13485", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " biotransformation [3, 4].\n\nLovastatin has a low oral bioava"}, {"to": "14719", "prefix": "cid concentrations as well as its lack of effect on plasma ", "from": "14709", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": ", it is unlikely that a clinically significant interaction w"}, {"to": "14809", "prefix": "t a clinically significant interaction would occur between ", "from": "14799", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " and higher dosages of itraconazole. In a recent study, AUC "}, {"to": "14891", "prefix": "dosages of itraconazole. In a recent study, AUC values for ", "from": "14881", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " were about 2-fold higher in hypercholesterolaemic renal tra"}, {"to": "14989", "prefix": " hypercholesterolaemic renal transplant patients receiving ", "from": "14979", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " 20 mg day"}, {"to": "15209", "prefix": " cyclosporine [14]. However, this difference in the AUC of ", "from": "15199", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " observed between the two groups may be related more to unde"}, {"to": "17179", "prefix": "reatly reduced while using CYP3A4 inhibitors. By contrast, ", "from": "17169", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " concentrations were not significantly increased by itracona"}, {"to": "17272", "prefix": "t significantly increased by itraconazole, indicating that ", "from": "17262", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " has much less potential than lovastatin for clinically sign"}, {"to": "17590", "prefix": "kinen-Pulli is greatly appreciated. Plasma ", "from": "17580", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1873980.txt", "exact": "fluvastatin", "suffix": " concentrations were kindly determined by Astra H"}, {"to": "96", "prefix": "of itraconazole on the pharmacokinetics of fluvastatin and ", "from": "87", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": ", two inhibitors of HMG-CoA reductase with different pharmac"}, {"to": "512", "prefix": "nce daily for 4 days. On day 4, 40 mg fluvastatin or 40 mg ", "from": "503", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " was administered orally. Plasma concentrations of fluvastat"}, {"to": "586", "prefix": "administered orally. Plasma concentrations of fluvastatin, ", "from": "577", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": ", lovastatin acid, itraconazole and hydroxyitraconazole were"}, {"to": "598", "prefix": " orally. Plasma concentrations of fluvastatin, lovastatin, ", "from": "589", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " acid, itraconazole and hydroxyitraconazole were determined "}, {"to": "1002", "prefix": ". The Cmax of ", "from": "993", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " was increased about 15-fold "}, {"to": "1149", "prefix": " by itraconazole. Similarly, the Cmax and total AUC of ", "from": "1140", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " acid were increased about 12-fold "}, {"to": "1321", "prefix": "2,z of ", "from": "1312", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " averaged 3.7"}, {"to": "1363", "prefix": "3.8 h and that of ", "from": "1354", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " acid 4.7"}, {"to": "1611", "prefix": "of 100 mg daily, greatly elevated plasma concentrations of ", "from": "1602", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " and its active metabolite, lovastatin acid. Lovastatin shou"}, {"to": "1649", "prefix": "ma concentrations of lovastatin and its active metabolite, ", "from": "1640", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " acid. Lovastatin should therefore not be used concomitantly"}, {"to": "1666", "prefix": " of lovastatin and its active metabolite, lovastatin acid. ", "from": "1657", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "Lovastatin", "suffix": " should therefore not be used concomitantly with itraconazol"}, {"to": "1791", "prefix": "azole and other potent CYP3A4 inhibitors, or the dosage of ", "from": "1782", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " should be greatly reduced while using a CYP3A4 inhibitor. I"}, {"to": "2007", "prefix": ", indicating that fluvastatin has much less potential than ", "from": "1998", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " for clinically significant interactions with itraconazole a"}, {"to": "2155", "prefix": "ibitors.\nKeywords: fluvastatin, interaction, itraconazole, ", "from": "2146", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": ", pharmacokinetics\nGo to:\nIntroduction\n\nFluvastatin and lova"}, {"to": "2221", "prefix": "tin, pharmacokinetics\nGo to:\nIntroduction\n\nFluvastatin and ", "from": "2212", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " are inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A "}, {"to": "2423", "prefix": "are widely used in the treatment of hypercholesterolaemia. ", "from": "2414", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "Lovastatin", "suffix": " is an inactive lactone pro-drug which is hydrolysed in vivo"}, {"to": "2497", "prefix": "n inactive lactone pro-drug which is hydrolysed in vivo to ", "from": "2488", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " acid, a competitive inhibitor of HMG-CoA reductase [1]. How"}, {"to": "2601", "prefix": "MG-CoA reductase [1]. However, the oxidative metabolism of ", "from": "2592", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " is primarily mediated by CYP3A4 [2]. The pharmacokinetics o"}, {"to": "2719", "prefix": "okinetics of fluvastatin differ considerably from those of ", "from": "2710", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": "; fluvastatin is not a pro-drug and it appears to be metabol"}, {"to": "2839", "prefix": "e metabolized mainly by CYP2C9 [3, 4].\n\nConcomitant use of ", "from": "2830", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " and, for example, cyclosporine, erythromycin or itraconazol"}, {"to": "3256", "prefix": "artly from inhibition of the CYP3A4-mediated metabolism of ", "from": "3247", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " [9]. The aim of the present study was to characterize the e"}, {"to": "3527", "prefix": " interact with CYP3A4 inhibitors such as itraconazole than ", "from": "3518", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": ".\nGo to:\nMethods\nSubjects\n\nTen healthy volunteers participat"}, {"to": "3713", "prefix": " and 10 in the ", "from": "3704", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " study "}, {"to": "4219", "prefix": " females who were using oral contraceptive steroids in the ", "from": "4210", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " and fluvastatin studies, respectively.\nStudy design\n\nTwo se"}, {"to": "4719", "prefix": " or 40 mg ", "from": "4710", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " "}, {"to": "4973", "prefix": "cts fasted for 1 h before administration of fluvastatin or ", "from": "4964", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": ". A warm standard meal was served 4 h and a light standard m"}, {"to": "5072", "prefix": "ved 4 h and a light standard meal 8 h after fluvastatin or ", "from": "5063", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " intake. The subjects were not allowed to drink grapefruit j"}, {"to": "5540", "prefix": " timed blood samples were drawn just before fluvastatin or ", "from": "5531", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " was administered and 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 h lat"}, {"to": "5792", "prefix": " C until analysis. Plasma concentrations of ", "from": "5783", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " and lovastatin acid were determined by high performance liq"}, {"to": "5807", "prefix": " C until analysis. Plasma concentrations of lovastatin and ", "from": "5798", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " acid were determined by high performance liquid chromatogra"}, {"to": "6117", "prefix": " for ", "from": "6108", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " and 7.8% "}, {"to": "6168", "prefix": " for ", "from": "6159", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " acid. The between-day CVs were 6.0% "}, {"to": "6280", "prefix": " for ", "from": "6271", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " and 8.3% "}, {"to": "6364", "prefix": " for ", "from": "6355", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " acid.\n\nFluvastatin concentrations were determined by h.p.l."}, {"to": "6817", "prefix": "ma itraconazole and hydroxyitraconazole levels between the ", "from": "6808", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " and fluvastatin studies, plasma itraconazole and hydroxyitr"}, {"to": "7545", "prefix": ".\nPharmacokinetics\n\nThe pharmacokinetics of fluvastatin, ", "from": "7536", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " and lovastatin acid were characterized, as appropriate, by "}, {"to": "7560", "prefix": "etics\n\nThe pharmacokinetics of fluvastatin, lovastatin and ", "from": "7551", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " acid were characterized, as appropriate, by peak concentrat"}, {"to": "8228", "prefix": "z for ", "from": "8219", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " and lovastatin acid could not be accurately determined in a"}, {"to": "8243", "prefix": "z for lovastatin and ", "from": "8234", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " acid could not be accurately determined in all subjects dur"}, {"to": "9834", "prefix": " and those of ", "from": "9825", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " 40 mg in 10 subjects "}, {"to": "9964", "prefix": " placebo or 100 mg itraconazole once daily for 4 days. ...\n", "from": "9955", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "Lovastatin", "suffix": " and lovastatin acid\n\nItraconazole considerably increased th"}, {"to": "9979", "prefix": " mg itraconazole once daily for 4 days. ...\nLovastatin and ", "from": "9970", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " acid\n\nItraconazole considerably increased the plasma concen"}, {"to": "10066", "prefix": "e considerably increased the plasma concentrations of both ", "from": "10057", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " and lovastatin acid, compared with placebo "}, {"to": "10081", "prefix": "increased the plasma concentrations of both lovastatin and ", "from": "10072", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " acid, compared with placebo "}, {"to": "10153", "prefix": ". The Cmax of ", "from": "10144", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " was increased about 15-fold "}, {"to": "10277", "prefix": "2,z of ", "from": "10268", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " averaged 3.7"}, {"to": "10448", "prefix": " due to the low plasma ", "from": "10439", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " concentrations.\nFigure 2\nFigure 2\nPlasma concentrations of "}, {"to": "10518", "prefix": "concentrations.\nFigure 2\nFigure 2\nPlasma concentrations of ", "from": "10509", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " "}, {"to": "10537", "prefix": " and ", "from": "10528", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " acid "}, {"to": "10626", "prefix": " after a 40 mg oral dose of ", "from": "10617", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": ", following pretreatment with 100 mg itraconazole "}, {"to": "10771", "prefix": " once daily ...\n\nThe Cmax and total AUC of ", "from": "10762", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " acid were increased about 12-fold "}, {"to": "10953", "prefix": "2,z of ", "from": "10944", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " acid was 4.7"}, {"to": "11259", "prefix": "etabolite hydroxyitraconazole on the day of fluvastatin or ", "from": "11250", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " administration are shown in Figure 3. The AUC "}, {"to": "11419", "prefix": "1 h in the ", "from": "11410", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " study and that of hydroxyitraconazole was 5497"}, {"to": "11747", "prefix": "open circles, fluvastatin study; closed circles, ", "from": "11738", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " study"}, {"to": "11843", "prefix": "open triangles, fluvastatin study; closed triangles, ", "from": "11834", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " study"}, {"to": "12019", "prefix": "udy demonstrate that plasma concentrations of the pro-drug ", "from": "12010", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " and its active metabolite, lovastatin acid, are greatly inc"}, {"to": "12057", "prefix": "ions of the pro-drug lovastatin and its active metabolite, ", "from": "12048", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " acid, are greatly increased by a daily dose of 100 mg itrac"}, {"to": "12386", "prefix": "e any clinical relevance. The increase in the total AUC of ", "from": "12377", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " acid by itraconazole was, on an average, 15-fold, but showe"}, {"to": "12559", "prefix": "zole appeared to have a similar effect on the total AUC of ", "from": "12550", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": "; however, this interaction could not be accurately quantifi"}, {"to": "12643", "prefix": " interaction could not be accurately quantified, since the ", "from": "12634", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " concentrations during the placebo phase were often below th"}, {"to": "12824", "prefix": "d agreement with the knowledge of the biotransformation of ", "from": "12815", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " and fluvastatin. The pro-drug lovastatin is partly hydrolys"}, {"to": "12865", "prefix": "transformation of lovastatin and fluvastatin. The pro-drug ", "from": "12856", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " is partly hydrolysed to the active metabolite, lovastatin a"}, {"to": "12923", "prefix": " lovastatin is partly hydrolysed to the active metabolite, ", "from": "12914", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " acid; this metabolic pathway is not dependent on the CYP en"}, {"to": "13057", "prefix": ". In contrast, formation of the other major metabolites of ", "from": "13048", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " is catalysed by CYP enzymes, primarily by CYP3A4 [2]. Thus,"}, {"to": "13155", "prefix": " primarily by CYP3A4 [2]. Thus, although the hydrolysis of ", "from": "13146", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " to lovastatin acid is not dependent on CYP3A4, inhibition o"}, {"to": "13169", "prefix": "CYP3A4 [2]. Thus, although the hydrolysis of lovastatin to ", "from": "13160", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " acid is not dependent on CYP3A4, inhibition of CYP3A4 by it"}, {"to": "13285", "prefix": " CYP3A4 by itraconazole results in greatly elevated plasma ", "from": "13276", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " concentrations, leading to a corresponding increase in lova"}, {"to": "13351", "prefix": "tin concentrations, leading to a corresponding increase in ", "from": "13342", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " acid levels. Unlike lovastatin, fluvastatin seems to be met"}, {"to": "13382", "prefix": "a corresponding increase in lovastatin acid levels. Unlike ", "from": "13373", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": ", fluvastatin seems to be metabolized primarily by CYP2C9; C"}, {"to": "13533", "prefix": "significant role in fluvastatin biotransformation [3, 4].\n\n", "from": "13524", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "Lovastatin", "suffix": " has a low oral bioavailability due to incomplete absorption"}, {"to": "13683", "prefix": "pass metabolism [13]. Considering that the Cmax and AUC of ", "from": "13674", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " and lovastatin acid were greatly increased by itraconazole,"}, {"to": "13698", "prefix": " [13]. Considering that the Cmax and AUC of lovastatin and ", "from": "13689", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " acid were greatly increased by itraconazole, with only a mi"}, {"to": "13935", "prefix": " wall and liver, it is likely that the interaction between ", "from": "13926", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " and itraconazole results mainly from inhibition of the CYP3"}, {"to": "14042", "prefix": "inhibition of the CYP3A4-mediated first-pass metabolism of ", "from": "14033", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": ".\n\nIn a previous study, a 4-day pretreatment with itraconazo"}, {"to": "14151", "prefix": "ment with itraconazole, 200 mg daily, increased the AUC of ", "from": "14142", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " and lovastatin acid about 20-fold [9]. One aim of the prese"}, {"to": "14166", "prefix": "onazole, 200 mg daily, increased the AUC of lovastatin and ", "from": "14157", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " acid about 20-fold [9]. One aim of the present study was to"}, {"to": "14306", "prefix": "he effect of a lower itraconazole dosage, 100 mg daily, on ", "from": "14297", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " pharmacokinetics. Although the lower itraconazole dosage ap"}, {"to": "14441", "prefix": " to have a slightly smaller effect on the plasma levels of ", "from": "14432", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " and lovastatin acid, it also is associated with a clinicall"}, {"to": "14456", "prefix": "htly smaller effect on the plasma levels of lovastatin and ", "from": "14447", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " acid, it also is associated with a clinically significant r"}, {"to": "14550", "prefix": "ted with a clinically significant risk of interaction with ", "from": "14541", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": ".\n\nConsidering the marked effect of itraconazole 100 mg dail"}, {"to": "14632", "prefix": "g the marked effect of itraconazole 100 mg daily on plasma ", "from": "14623", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " and lovastatin acid concentrations as well as its lack of e"}, {"to": "14647", "prefix": "fect of itraconazole 100 mg daily on plasma lovastatin and ", "from": "14638", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " acid concentrations as well as its lack of effect on plasma"}, {"to": "15805", "prefix": " incidence and severity of the skeletal muscle toxicity of ", "from": "15796", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " [5, 6, 8]. In addition, a severe case of rhabdomyolysis occ"}, {"to": "15942", "prefix": " and ", "from": "15933", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " has been reported [7]. These interactions probably result f"}, {"to": "16072", "prefix": "om the greatly elevated blood and tissue concentrations of ", "from": "16063", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " acid; normally, monotherapy with lovastatin is well tolerat"}, {"to": "16116", "prefix": "centrations of lovastatin acid; normally, monotherapy with ", "from": "16107", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " is well tolerated due to the low levels of lovastatin acid."}, {"to": "16170", "prefix": "with lovastatin is well tolerated due to the low levels of ", "from": "16161", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " acid.\n\nThe biotransformation of the pro-drug simvastatin is"}, {"to": "16260", "prefix": "ormation of the pro-drug simvastatin is similar to that of ", "from": "16251", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " [13] and it might therefore be expected that simvastatin wo"}, {"to": "16929", "prefix": "of 100 mg daily, greatly elevates plasma concentrations of ", "from": "16920", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " and its active metabolite, lovastatin acid. Lovastatin "}, {"to": "16967", "prefix": "ma concentrations of lovastatin and its active metabolite, ", "from": "16958", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " acid. Lovastatin "}, {"to": "16984", "prefix": " of lovastatin and its active metabolite, lovastatin acid. ", "from": "16975", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "Lovastatin", "suffix": " "}, {"to": "17312", "prefix": ", indicating that fluvastatin has much less potential than ", "from": "17303", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1873980.txt", "exact": "lovastatin", "suffix": " for clinically significant interactions with itraconazole a"}, {"to": "4732", "prefix": "one ", "from": "4726", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "PMC1873980.txt", "exact": "Mevacor", "suffix": " 40 mg tablet, Merck Sharp & Dohme B.V., Haarlem, Netherland"}, {"to": "641", "prefix": "fluvastatin, lovastatin, lovastatin acid, itraconazole and ", "from": "623", "name": "hydroxyitraconazole", "fullId": "http://purl.bioontology.org/ontology/MESH/C084794", "setId": "PMC1873980.txt", "exact": "hydroxyitraconazole", "suffix": " were determined up to 24 h.\nResults\n\nItraconazole had no si"}, {"to": "6787", "prefix": ".\n\nTo assess the comparability of plasma itraconazole and ", "from": "6769", "name": "hydroxyitraconazole", "fullId": "http://purl.bioontology.org/ontology/MESH/C084794", "setId": "PMC1873980.txt", "exact": "hydroxyitraconazole", "suffix": " levels between the lovastatin and fluvastatin studies, plas"}, {"to": "6886", "prefix": "ovastatin and fluvastatin studies, plasma itraconazole and ", "from": "6868", "name": "hydroxyitraconazole", "fullId": "http://purl.bioontology.org/ontology/MESH/C084794", "setId": "PMC1873980.txt", "exact": "hydroxyitraconazole", "suffix": " concentrations were determined in all samples, i.e. from 1 "}, {"to": "7038", "prefix": "st itraconazole dose on day 4 up to 25 h. Itraconazole and ", "from": "7020", "name": "hydroxyitraconazole", "fullId": "http://purl.bioontology.org/ontology/MESH/C084794", "setId": "PMC1873980.txt", "exact": "hydroxyitraconazole", "suffix": " concentrations were determined by h.p.l.c. as previously de"}, {"to": "7378", "prefix": " for ", "from": "7360", "name": "hydroxyitraconazole", "fullId": "http://purl.bioontology.org/ontology/MESH/C084794", "setId": "PMC1873980.txt", "exact": "hydroxyitraconazole", "suffix": ". At a mean concentration of about 20 ng ml"}, {"to": "8404", "prefix": "ue to low plasma drug concentrations. For itraconazole and ", "from": "8386", "name": "hydroxyitraconazole", "fullId": "http://purl.bioontology.org/ontology/MESH/C084794", "setId": "PMC1873980.txt", "exact": "hydroxyitraconazole", "suffix": ", the AUC "}, {"to": "11125", "prefix": "d in only five subjects, averaging 6.1 h.\nItraconazole and ", "from": "11107", "name": "hydroxyitraconazole", "fullId": "http://purl.bioontology.org/ontology/MESH/C084794", "setId": "PMC1873980.txt", "exact": "hydroxyitraconazole", "suffix": "\n\nThe mean plasma concentrations of itraconazole and its act"}, {"to": "11219", "prefix": "a concentrations of itraconazole and its active metabolite ", "from": "11201", "name": "hydroxyitraconazole", "fullId": "http://purl.bioontology.org/ontology/MESH/C084794", "setId": "PMC1873980.txt", "exact": "hydroxyitraconazole", "suffix": " on the day of fluvastatin or lovastatin administration are "}, {"to": "11457", "prefix": "1 h in the lovastatin study and that of ", "from": "11439", "name": "hydroxyitraconazole", "fullId": "http://purl.bioontology.org/ontology/MESH/C084794", "setId": "PMC1873980.txt", "exact": "hydroxyitraconazole", "suffix": " was 5497"}, {"to": "11605", "prefix": " of itraconazole or ", "from": "11587", "name": "hydroxyitraconazole", "fullId": "http://purl.bioontology.org/ontology/MESH/C084794", "setId": "PMC1873980.txt", "exact": "hydroxyitraconazole", "suffix": " between the two studies.\nFigure 3\nFigure 3\nPlasma concentra"}, {"to": "11778", "prefix": " and ", "from": "11760", "name": "hydroxyitraconazole", "fullId": "http://purl.bioontology.org/ontology/MESH/C084794", "setId": "PMC1873980.txt", "exact": "hydroxyitraconazole", "suffix": " "}, {"to": "2336", "prefix": " reductase, the rate-limiting step in ", "from": "2326", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC1873980.txt", "exact": "cholesterol", "suffix": " synthesis, which are widely used in the treatment of hyperc"}, {"to": "2870", "prefix": "9 [3, 4].\n\nConcomitant use of lovastatin and, for example, ", "from": "2859", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016572", "setId": "PMC1873980.txt", "exact": "cyclosporine", "suffix": ", erythromycin or itraconazole is associated with a consider"}, {"to": "15033", "prefix": "1 concomitantly with ", "from": "15022", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016572", "setId": "PMC1873980.txt", "exact": "cyclosporine", "suffix": " than in hypercholesterolaemic patients who had not undergon"}, {"to": "15152", "prefix": "not undergone renal transplantation and were not receiving ", "from": "15141", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016572", "setId": "PMC1873980.txt", "exact": "cyclosporine", "suffix": " [14]. However, this difference in the AUC of fluvastatin ob"}, {"to": "15367", "prefix": "creased renal function, in the transplant patients than to ", "from": "15356", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016572", "setId": "PMC1873980.txt", "exact": "cyclosporine", "suffix": " therapy. In any event, it should be noted that apart from i"}, {"to": "15457", "prefix": "ent, it should be noted that apart from inhibiting CYP3A4, ", "from": "15446", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016572", "setId": "PMC1873980.txt", "exact": "cyclosporine", "suffix": " and itraconazole may increase plasma concentrations of HMG-"}, {"to": "15688", "prefix": " 16].\n\nConcomitant administration of the CYP3A4 inhibitors ", "from": "15677", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016572", "setId": "PMC1873980.txt", "exact": "cyclosporine", "suffix": " and erythromycin has been shown to increase the incidence a"}, {"to": "16544", "prefix": "hat concomitant therapy with simvastatin and itraconazole, ", "from": "16533", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016572", "setId": "PMC1873980.txt", "exact": "cyclosporine", "suffix": " or other CYP3A4 inhibitors predisposes to myositis and rhab"}, {"to": "2884", "prefix": "comitant use of lovastatin and, for example, cyclosporine, ", "from": "2873", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "PMC1873980.txt", "exact": "erythromycin", "suffix": " or itraconazole is associated with a considerably increased"}, {"to": "15705", "prefix": "t administration of the CYP3A4 inhibitors cyclosporine and ", "from": "15694", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "PMC1873980.txt", "exact": "erythromycin", "suffix": " has been shown to increase the incidence and severity of th"}, {"to": "4016", "prefix": "including blood haemoglobin, serum creatine kinase, ", "from": "4007", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003404", "setId": "PMC1873980.txt", "exact": "creatinine", "suffix": " and alanine aminotransferase"}, {"to": "4028", "prefix": "g blood haemoglobin, serum creatine kinase, creatinine and ", "from": "4022", "name": "Alanine", "fullId": "http://purl.bioontology.org/ontology/MESH/D000409", "setId": "PMC1873980.txt", "exact": "alanine", "suffix": " aminotransferase"}, {"to": "5710", "prefix": "", "from": "5707", "name": "Edetic Acid", "fullId": "http://purl.bioontology.org/ontology/MESH/D004492", "setId": "PMC1873980.txt", "exact": "EDTA", "suffix": ""}, {"to": "5924", "prefix": ", as previously described [10]. ", "from": "5914", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC1873980.txt", "exact": "Simvastatin", "suffix": " was used as an internal standard. The limit of quantificati"}, {"to": "16227", "prefix": "of lovastatin acid.\n\nThe biotransformation of the pro-drug ", "from": "16217", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC1873980.txt", "exact": "simvastatin", "suffix": " is similar to that of lovastatin [13] and it might therefor"}, {"to": "16317", "prefix": "of lovastatin [13] and it might therefore be expected that ", "from": "16307", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC1873980.txt", "exact": "simvastatin", "suffix": " would also interact with itraconazole and other potent CYP3"}, {"to": "16513", "prefix": "recent case reports indicate that concomitant therapy with ", "from": "16503", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC1873980.txt", "exact": "simvastatin", "suffix": " and itraconazole, cyclosporine or other CYP3A4 inhibitors p"}, {"to": "17001", "prefix": "and ", "from": "16991", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC1873980.txt", "exact": "simvastatin", "suffix": ""}, {"to": "53", "prefix": "Abstract\n\nAims\n\nTo evaluate the effects of ", "from": "44", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "PMC2015049.txt", "exact": "cimetidine", "suffix": " and Maalox"}, {"to": "437", "prefix": "another occasion ziprasidone was co-administered with oral ", "from": "428", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "PMC2015049.txt", "exact": "cimetidine", "suffix": " 800 mg and on a third occasion ziprasidone was co-administe"}, {"to": "561", "prefix": ".\nResults\n\nThe administration of ", "from": "552", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "PMC2015049.txt", "exact": "cimetidine", "suffix": " increased the ziprasidone AUC"}, {"to": "716", "prefix": " ", "from": "707", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "PMC2015049.txt", "exact": "cimetidine", "suffix": " group and the ziprasidone group. The administration of Maal"}, {"to": "1044", "prefix": "prasidone are not affected by concurrent administration of ", "from": "1035", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "PMC2015049.txt", "exact": "cimetidine", "suffix": " or Maalox"}, {"to": "1240", "prefix": "kinetics of ziprasidone.\nKeywords: ziprasidone, aluminium, ", "from": "1231", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "PMC2015049.txt", "exact": "cimetidine", "suffix": ", interaction, magnesium, pharmacokinetics\n\nIntroduction\n\nZi"}, {"to": "1821", "prefix": "improved drug solubilization in the presence of food [3].\n\n", "from": "1812", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "PMC2015049.txt", "exact": "Cimetidine", "suffix": " is an H2 receptor antagonist which is commonly used to trea"}, {"to": "2179", "prefix": "h are also oxidatively metabolized by CYP3A4. In addition, ", "from": "2170", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "PMC2015049.txt", "exact": "cimetidine", "suffix": " can alter gastric pH and therefore has the potential to aff"}, {"to": "2758", "prefix": "udy was designed to determine whether or not multiple-dose ", "from": "2749", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "PMC2015049.txt", "exact": "cimetidine", "suffix": " or antacid administration alters the pharmacokinetics of zi"}, {"to": "3270", "prefix": "over study designed to determine whether multiple doses of ", "from": "3261", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "PMC2015049.txt", "exact": "cimetidine", "suffix": " and Maalox"}, {"to": "3740", "prefix": " ", "from": "3731", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "PMC2015049.txt", "exact": "cimetidine", "suffix": " 800 mg; and ziprasidone 40 mg "}, {"to": "3972", "prefix": "ally, after a standard breakfast at approximately 09.00 h. ", "from": "3963", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "PMC2015049.txt", "exact": "Cimetidine", "suffix": " tablets were administered once daily, at approximately 07.0"}, {"to": "7606", "prefix": " ", "from": "7597", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "PMC2015049.txt", "exact": "cimetidine", "suffix": " treatment periods.\nPharmacokinetics\n\nThe mean serum ziprasi"}, {"to": "8104", "prefix": " ", "from": "8095", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "PMC2015049.txt", "exact": "cimetidine", "suffix": " "}, {"to": "8500", "prefix": " ", "from": "8491", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "PMC2015049.txt", "exact": "cimetidine", "suffix": " group with the ziprasidone alone group. This parameter was "}, {"to": "8604", "prefix": " ", "from": "8595", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "PMC2015049.txt", "exact": "cimetidine", "suffix": " group than in the ziprasidone alone group "}, {"to": "8750", "prefix": " ", "from": "8741", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "PMC2015049.txt", "exact": "cimetidine", "suffix": " group and the ziprasidone alone group was statistically sig"}, {"to": "8875", "prefix": " ", "from": "8866", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "PMC2015049.txt", "exact": "cimetidine", "suffix": " group was 3.1% longer than that in the ziprasidone alone gr"}, {"to": "9138", "prefix": " ", "from": "9129", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "PMC2015049.txt", "exact": "cimetidine", "suffix": " "}, {"to": "9317", "prefix": " ", "from": "9308", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "PMC2015049.txt", "exact": "cimetidine", "suffix": " "}, {"to": "9756", "prefix": "rom this study indicate that concomitant administration of ", "from": "9747", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "PMC2015049.txt", "exact": "cimetidine", "suffix": " produces a small increase in systemic exposure to ziprasido"}, {"to": "10134", "prefix": " ", "from": "10125", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "PMC2015049.txt", "exact": "cimetidine", "suffix": " and ziprasidone alone groups. Similarly, no statistically s"}, {"to": "10471", "prefix": " relevance.\n\nThe lack of clinically significant effects of ", "from": "10462", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "PMC2015049.txt", "exact": "cimetidine", "suffix": " on the pharmacokinetics of ziprasidone was observed despite"}, {"to": "10629", "prefix": "asidone metabolism is primarily mediated by CYP3A4 [2]. As ", "from": "10620", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "PMC2015049.txt", "exact": "cimetidine", "suffix": " is known to be a non-specific inhibitor of CYP3A4 [4], the "}, {"to": "11177", "prefix": "changed to a greater degree than normal in the presence of ", "from": "11168", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "PMC2015049.txt", "exact": "cimetidine", "suffix": ".\n\nIn conclusion, the findings of this study indicate that t"}, {"to": "11286", "prefix": "tudy indicate that the administration of multiple doses of ", "from": "11277", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "PMC2015049.txt", "exact": "cimetidine", "suffix": " or of Maalox"}, {"to": "64", "prefix": "Abstract\n\nAims\n\nTo evaluate the effects of cimetidine and ", "from": "59", "name": "Maalox", "fullId": "http://purl.bioontology.org/ontology/RXNORM/29115", "setId": "PMC2015049.txt", "exact": "Maalox", "suffix": ""}, {"to": "517", "prefix": "a third occasion ziprasidone was co-administered with oral ", "from": "512", "name": "Maalox", "fullId": "http://purl.bioontology.org/ontology/RXNORM/29115", "setId": "PMC2015049.txt", "exact": "Maalox", "suffix": ""}, {"to": "778", "prefix": "ine group and the ziprasidone group. The administration of ", "from": "773", "name": "Maalox", "fullId": "http://purl.bioontology.org/ontology/RXNORM/29115", "setId": "PMC2015049.txt", "exact": "Maalox", "suffix": ""}, {"to": "901", "prefix": " ", "from": "896", "name": "Maalox", "fullId": "http://purl.bioontology.org/ontology/RXNORM/29115", "setId": "PMC2015049.txt", "exact": "Maalox", "suffix": ""}, {"to": "1054", "prefix": "not affected by concurrent administration of cimetidine or ", "from": "1049", "name": "Maalox", "fullId": "http://purl.bioontology.org/ontology/RXNORM/29115", "setId": "PMC2015049.txt", "exact": "Maalox", "suffix": ""}, {"to": "3281", "prefix": "gned to determine whether multiple doses of cimetidine and ", "from": "3276", "name": "Maalox", "fullId": "http://purl.bioontology.org/ontology/RXNORM/29115", "setId": "PMC2015049.txt", "exact": "Maalox", "suffix": ""}, {"to": "3779", "prefix": " ", "from": "3774", "name": "Maalox", "fullId": "http://purl.bioontology.org/ontology/RXNORM/29115", "setId": "PMC2015049.txt", "exact": "Maalox", "suffix": ""}, {"to": "4147", "prefix": "ation and continuing until 1 day after ziprasidone dosing. ", "from": "4142", "name": "Maalox", "fullId": "http://purl.bioontology.org/ontology/RXNORM/29115", "setId": "PMC2015049.txt", "exact": "Maalox", "suffix": ""}, {"to": "7576", "prefix": " ", "from": "7571", "name": "Maalox", "fullId": "http://purl.bioontology.org/ontology/RXNORM/29115", "setId": "PMC2015049.txt", "exact": "Maalox", "suffix": ""}, {"to": "7865", "prefix": " ", "from": "7860", "name": "Maalox", "fullId": "http://purl.bioontology.org/ontology/RXNORM/29115", "setId": "PMC2015049.txt", "exact": "Maalox", "suffix": ""}, {"to": "8076", "prefix": " ", "from": "8071", "name": "Maalox", "fullId": "http://purl.bioontology.org/ontology/RXNORM/29115", "setId": "PMC2015049.txt", "exact": "Maalox", "suffix": ""}, {"to": "9110", "prefix": " ", "from": "9105", "name": "Maalox", "fullId": "http://purl.bioontology.org/ontology/RXNORM/29115", "setId": "PMC2015049.txt", "exact": "Maalox", "suffix": ""}, {"to": "9289", "prefix": " ", "from": "9284", "name": "Maalox", "fullId": "http://purl.bioontology.org/ontology/RXNORM/29115", "setId": "PMC2015049.txt", "exact": "Maalox", "suffix": ""}, {"to": "9444", "prefix": " ", "from": "9439", "name": "Maalox", "fullId": "http://purl.bioontology.org/ontology/RXNORM/29115", "setId": "PMC2015049.txt", "exact": "Maalox", "suffix": ""}, {"to": "9579", "prefix": " ", "from": "9574", "name": "Maalox", "fullId": "http://purl.bioontology.org/ontology/RXNORM/29115", "setId": "PMC2015049.txt", "exact": "Maalox", "suffix": ""}, {"to": "10249", "prefix": " ", "from": "10244", "name": "Maalox", "fullId": "http://purl.bioontology.org/ontology/RXNORM/29115", "setId": "PMC2015049.txt", "exact": "Maalox", "suffix": ""}, {"to": "11299", "prefix": "t the administration of multiple doses of cimetidine or of ", "from": "11294", "name": "Maalox", "fullId": "http://purl.bioontology.org/ontology/RXNORM/29115", "setId": "PMC2015049.txt", "exact": "Maalox", "suffix": ""}, {"to": "163", "prefix": " on the pharmacokinetics of ", "from": "153", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": ".\nMethods\n\nEleven healthy young subjects aged 18"}, {"to": "264", "prefix": "45 years were given single oral doses of ", "from": "254", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " 40 mg on three occasions at least 7 days apart. On one occa"}, {"to": "340", "prefix": " on three occasions at least 7 days apart. On one occasion ", "from": "330", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " was administered alone, on another occasion ziprasidone was"}, {"to": "396", "prefix": "on ziprasidone was administered alone, on another occasion ", "from": "386", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " was co-administered with oral cimetidine 800 mg and on a th"}, {"to": "480", "prefix": "stered with oral cimetidine 800 mg and on a third occasion ", "from": "470", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " was co-administered with oral Maalox"}, {"to": "587", "prefix": ".\nResults\n\nThe administration of cimetidine increased the ", "from": "577", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " AUC"}, {"to": "703", "prefix": "z between the ", "from": "693", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " "}, {"to": "742", "prefix": " cimetidine group and the ", "from": "732", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " group. The administration of Maalox"}, {"to": "892", "prefix": "z between the ", "from": "882", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " "}, {"to": "928", "prefix": " group and the ", "from": "918", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " group.\nConclusions\n\nThe pharmacokinetics of ziprasidone are"}, {"to": "984", "prefix": "he ziprasidone group.\nConclusions\n\nThe pharmacokinetics of ", "from": "974", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " are not affected by concurrent administration of cimetidine"}, {"to": "1194", "prefix": "and antacids are unlikely to alter the pharmacokinetics of ", "from": "1184", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": ".\nKeywords: ziprasidone, aluminium, cimetidine, interaction,"}, {"to": "1217", "prefix": "ly to alter the pharmacokinetics of ziprasidone.\nKeywords: ", "from": "1207", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": ", aluminium, cimetidine, interaction, magnesium, pharmacokin"}, {"to": "1309", "prefix": "e, interaction, magnesium, pharmacokinetics\n\nIntroduction\n\n", "from": "1299", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "Ziprasidone", "suffix": " has a pharmacokinetic profile unaffected by age and gender "}, {"to": "1544", "prefix": "ver microsomes have shown that the oxidative metabolism of ", "from": "1534", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " is primarily mediated by the 3A4 isoform of cytochrome P450"}, {"to": "1668", "prefix": " [2]. The absorption of orally administered ", "from": "1658", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " is enhanced when it is taken immediately after eating, perh"}, {"to": "2827", "prefix": "e or antacid administration alters the pharmacokinetics of ", "from": "2817", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": ".\nGo to:\nMethods\nSubjects\n\nThe subjects were healthy, young "}, {"to": "3324", "prefix": " alter the pharmacokinetics of ", "from": "3314", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": ". The study protocol was approved by an independent institut"}, {"to": "3696", "prefix": "uter-generated randomization. These three treatments were: ", "from": "3686", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " 40 mg alone; ziprasidone 40 mg "}, {"to": "3721", "prefix": "ion. These three treatments were: ziprasidone 40 mg alone; ", "from": "3711", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " 40 mg "}, {"to": "3764", "prefix": " cimetidine 800 mg; and ", "from": "3754", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " 40 mg "}, {"to": "3873", "prefix": ".\n\n", "from": "3849", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "Ziprasidone hydrochloride", "suffix": " capsules were administered orally, after a standard breakfa"}, {"to": "4072", "prefix": "e daily, at approximately 07.00h, commencing 2 days before ", "from": "4062", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " administration and continuing until 1 day after ziprasidone"}, {"to": "4132", "prefix": "iprasidone administration and continuing until 1 day after ", "from": "4122", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " dosing. Maalox"}, {"to": "4232", "prefix": "s administered on the evening before the administration of ", "from": "4222", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " "}, {"to": "4292", "prefix": ", immediately before the ", "from": "4282", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " dosing "}, {"to": "4427", "prefix": " on the day that ", "from": "4417", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " was taken.\nPharmacokinetic sampling\n\nBlood samples for the "}, {"to": "4521", "prefix": "tic sampling\n\nBlood samples for the determination of serum ", "from": "4511", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " concentrations were collected immediately before dosing and"}, {"to": "4642", "prefix": "osing and at fixed intervals up to 36 h after each dose of ", "from": "4632", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": ".\nPharmacokinetic analysis\n\nSerum concentrations of ziprasid"}, {"to": "4705", "prefix": "asidone.\nPharmacokinetic analysis\n\nSerum concentrations of ", "from": "4695", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " were determined using high performance liquid chromatograph"}, {"to": "4886", "prefix": "1[6]. ", "from": "4876", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "Ziprasidone", "suffix": " concentrations below the lower limit of quantification were"}, {"to": "5057", "prefix": "okinetic calculations.\n\nThe maximum serum concentration of ", "from": "5047", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " "}, {"to": "5223", "prefix": "erimental data. The terminal elimination rate constant for ", "from": "5213", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " "}, {"to": "5301", "prefix": "s estimated using least-squares regression analysis of the ", "from": "5291", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " concentration"}, {"to": "5410", "prefix": "g the terminal log-linear phase. The terminal half-life of ", "from": "5400", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " "}, {"to": "5482", "prefix": "z, and the mean half-life of ", "from": "5472", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " was estimated as ln 2"}, {"to": "5617", "prefix": " serum ", "from": "5607", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " was measurable "}, {"to": "5895", "prefix": "pest is the estimated concentration at the last time serum ", "from": "5885", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " was measurable based on the regression analysis of the term"}, {"to": "7456", "prefix": "y after experiencing adverse events and only completed the ", "from": "7446", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " treatment period. Another subject discontinued the study fo"}, {"to": "7567", "prefix": "tinued the study for personal reasons after completing the ", "from": "7557", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " "}, {"to": "7593", "prefix": " and ", "from": "7583", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " "}, {"to": "7670", "prefix": "tidine treatment periods.\nPharmacokinetics\n\nThe mean serum ", "from": "7660", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " concentration"}, {"to": "7856", "prefix": "tically significant delay in the occurrence of Cmax in the ", "from": "7846", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " "}, {"to": "7902", "prefix": " group compared with the ", "from": "7892", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " alone group "}, {"to": "8005", "prefix": ".\nFigure 1\nFigure 1\nMean serum ", "from": "7995", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " concentrations by treatment group "}, {"to": "8052", "prefix": "", "from": "8042", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " "}, {"to": "8067", "prefix": "; ", "from": "8057", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " "}, {"to": "8091", "prefix": "; ", "from": "8081", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " "}, {"to": "8156", "prefix": ".\n\nThe pharmacokinetic parameters for ", "from": "8146", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " across the three treatment groups were generally similar "}, {"to": "8487", "prefix": " values in the ", "from": "8477", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " "}, {"to": "8527", "prefix": " cimetidine group with the ", "from": "8517", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " alone group. This parameter was 6.2% greater in the ziprasi"}, {"to": "8591", "prefix": "sidone alone group. This parameter was 6.2% greater in the ", "from": "8581", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " "}, {"to": "8634", "prefix": " cimetidine group than in the ", "from": "8624", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " alone group "}, {"to": "8737", "prefix": "z between the ", "from": "8727", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " "}, {"to": "8776", "prefix": " cimetidine group and the ", "from": "8766", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " alone group was statistically significant. The t"}, {"to": "8843", "prefix": ",z of ", "from": "8833", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " in the ziprasidone "}, {"to": "8862", "prefix": ",z of ziprasidone in the ", "from": "8852", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " "}, {"to": "8926", "prefix": " cimetidine group was 3.1% longer than that in the ", "from": "8916", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " alone group.\nTable 2\nTable 2\nSummary of pharmacokinetic par"}, {"to": "9008", "prefix": ".\nTable 2\nTable 2\nSummary of pharmacokinetic parameters of ", "from": "8998", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": ".\nFigure 2\nFigure 2\nIndividual AUC"}, {"to": "9086", "prefix": "", "from": "9076", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " "}, {"to": "9101", "prefix": "; ", "from": "9091", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " "}, {"to": "9125", "prefix": "; ", "from": "9115", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " "}, {"to": "9265", "prefix": "", "from": "9255", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " "}, {"to": "9280", "prefix": "; ", "from": "9270", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " "}, {"to": "9304", "prefix": "; ", "from": "9294", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " "}, {"to": "9435", "prefix": "z values in the ", "from": "9425", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " "}, {"to": "9514", "prefix": " group were not significantly different from those in the ", "from": "9504", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " alone group. The t"}, {"to": "9551", "prefix": ",z of ", "from": "9541", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " in the ziprasidone "}, {"to": "9570", "prefix": ",z of ziprasidone in the ", "from": "9560", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " "}, {"to": "9650", "prefix": " group was almost identical to that in the group receiving ", "from": "9640", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " alone.\nGo to:\nDiscussion\n\nFindings from this study indicate"}, {"to": "9818", "prefix": "metidine produces a small increase in systemic exposure to ", "from": "9808", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " as measured by the AUC"}, {"to": "10121", "prefix": "stically or clinically significant differences between the ", "from": "10111", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " "}, {"to": "10150", "prefix": " cimetidine and ", "from": "10140", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " alone groups. Similarly, no statistically significant diffe"}, {"to": "10240", "prefix": "arly, no statistically significant differences between the ", "from": "10230", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " "}, {"to": "10266", "prefix": " and ", "from": "10256", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " alone groups were observed for any of the measured pharmaco"}, {"to": "10510", "prefix": "gnificant effects of cimetidine on the pharmacokinetics of ", "from": "10500", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " was observed despite the fact that oxidative ziprasidone me"}, {"to": "10567", "prefix": "f ziprasidone was observed despite the fact that oxidative ", "from": "10557", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " metabolism is primarily mediated by CYP3A4 [2]. As cimetidi"}, {"to": "10736", "prefix": "tor of CYP3A4 [4], the findings of this study suggest that ", "from": "10726", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " could also be metabolized via alternative pathways. In view"}, {"to": "10836", "prefix": " alternative pathways. In view of the in vitro activity of ", "from": "10826", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " for the inhibition of CYP3A4 [4], however, a single dose of"}, {"to": "10908", "prefix": "or the inhibition of CYP3A4 [4], however, a single dose of ", "from": "10898", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " would seem unlikely to inhibit this isoenzyme substantially"}, {"to": "11089", "prefix": " is in accord with this hypothesis. Alternatively, ", "from": "11079", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " may be excreted unchanged to a greater degree than normal i"}, {"to": "11401", "prefix": "gnificant influence on the single-dose pharmacokinetics of ", "from": "11391", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092292", "setId": "PMC2015049.txt", "exact": "ziprasidone", "suffix": " 40 mg.\n"}]